These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3493624)

  • 1. Changes in the local cerebral metabolic rate for glucose in the MPTP primate model of Parkinson's disease.
    Schwartzman RJ; Alexander GM
    Adv Neurol; 1987; 45():171-3. PubMed ID: 3493624
    [No Abstract]   [Full Text] [Related]  

  • 2. [MPTP and Parkinson's disease].
    Imai H
    No To Shinkei; 1988 Nov; 40(11):1011-24. PubMed ID: 3064783
    [No Abstract]   [Full Text] [Related]  

  • 3. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
    Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E
    Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease.
    Schwartzman RJ; Alexander GM
    Brain Res; 1985 Dec; 358(1-2):137-43. PubMed ID: 3878182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPTP in animal models of Parkinson's disease.
    Kopin IJ; Schoenberg DG
    Mt Sinai J Med; 1988 Jan; 55(1):43-9. PubMed ID: 3126391
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys.
    Ho VW; Porrino LJ; Crane AM; Burns RS; Kopin IJ; Sokoloff L
    Ann Neurol; 1988 Jan; 23(1):86-9. PubMed ID: 3257855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary (toxic) parkinsonism as model of Parkinson's disease.
    Riederer P; Sofic E; Heuschneider G; Benedetti MS; Dostert P
    Funct Neurol; 1988; 3(4):449-57. PubMed ID: 3072280
    [No Abstract]   [Full Text] [Related]  

  • 8. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
    Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF
    Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
    Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L
    Life Sci; 1987 Apr; 40(17):1657-64. PubMed ID: 3494179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.
    Aziz TZ; Peggs D; Sambrook MA; Crossman AR
    Mov Disord; 1991; 6(4):288-92. PubMed ID: 1758446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract]   [Full Text] [Related]  

  • 12. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985.
    J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069
    [No Abstract]   [Full Text] [Related]  

  • 13. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey.
    Crossman AR; Mitchell IJ; Sambrook MA
    Neuropharmacology; 1985 Jun; 24(6):587-91. PubMed ID: 3875056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.
    Chiueh CC; Markey SP; Burns RS; Johannessen JN; Jacobowitz DM; Kopin IJ
    Psychopharmacol Bull; 1984; 20(3):548-53. PubMed ID: 6332333
    [No Abstract]   [Full Text] [Related]  

  • 15. [Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Renkawek K
    Neuropatol Pol; 1986; 24(1):1-8. PubMed ID: 3489205
    [No Abstract]   [Full Text] [Related]  

  • 16. [Parkinsonism and MPTP (methylphenyltetrahydropyridine)].
    Nagatsu T
    No To Shinkei; 1986 Jul; 38(7):706-7. PubMed ID: 3489476
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experimental parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine].
    Kryzhanovskiĭ GN; Atadzhanov MA; Zagorevskiĭ VA; Sharkova LM; Voronina TA
    Biull Eksp Biol Med; 1988 Apr; 105(4):397-401. PubMed ID: 3258764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPTP-induced parkinsonism. Recent studies on the mechanism of toxicity.
    Bocchetta A; Piccardi MP; Zuddas A; Bernardi F; Zompo MD; Corsini GU
    Funct Neurol; 1988; 3(4):439-47. PubMed ID: 3072279
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
    Cohen G
    Adv Neurol; 1987; 45():119-25. PubMed ID: 3030068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.